56 results
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
27 Jul 15
Capnia Announces $10 Million At-the-Market Firm Commitment Stock Purchase Agreement with Aspire Capital
12:00am
-7-
Market, other than routine matters incident to listing on the Principal Market and not involving a violation of the rules of the Principal … of the Purchase Agreement, the documents incident thereto and other factors deemed relevant by the Board of Directors, the Board of Directors has
8-K
EX-10.1
SLNO
Soleno Therapeutics Inc
5 Mar 15
Capnia Announces Receipt of $3.6 million From Series B Warrant Exercise and Issuance of Series C Warrants
12:00am
by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all transfer agent fees
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
, the Subsidiaries or any of their properties or assets to notify in writing, any person of any Personal Data or security-related incident. Neither … , the Company hereby agrees to pay all costs and expenses incident to the performance of its obligations hereunder, including the following: (i) all expenses
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
or not the transactions contemplated hereby are consummated or this Agreement is terminated, all costs and expenses incident to the public offering of the Shares … to the Underwriters, and (viii) all reasonableout-of-pocket costs and reasonable expenses incident to the offering and the performance
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
the Company, the Subsidiaries or any of their properties or assets to notify in writing, any person of any Personal Data or security-related incident … , the Company hereby agrees to pay all costs and expenses incident to the performance of its obligations hereunder, including the following: (i) all
8-K
EX-1.1
shm27 4wix
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
8-K
EX-1.1
pxze106n9s9lo
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
8-K
EX-1.2
rm05rky3
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B3
i0a 6lvh7av
14 Oct 15
Prospectus supplement
12:00am
S-1/A
EX-3.3
s0lyygqzt8yr9 l9ap
1 Jul 14
IPO registration (amended)
12:00am
8-K
EX-10.1
ggjtz s7uo6
19 Dec 18
Soleno Therapeutics Announces $16.5 Million Private Placement
4:02pm
8-K
EX-10.1
f0oq b6i9
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-10.1
672smuf4gzo6
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
552 9smfan346jk
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
S-1/A
EX-3.4
zcp1zijcdlmzf sbexh
1 Jul 14
IPO registration (amended)
12:00am